Table 1.
Clinical, pathological and immunohistochemical data of 173 untreated primary ER+ and/or HER2+ breast carcinomas studied by TMA
| ΔNp63/p40− (n = 73) | ΔNp63/p40+ (n = 100) | P value | |
|---|---|---|---|
| ER | 61 | 81 | 0.061 |
| ERH | 3 | 13 | |
| H | 9 | 6 | |
| HER2 | 12 | 19 | |
| TP53 mutant | 17 | 20 | 0.740 |
| TP53 wt | 56 | 80 | |
| Grades 1–2 | 45 | 59 | 0.729 |
| Grade 3 | 26 | 40 | |
| Positive nodes | 36 | 43 | 0.527 |
| Negative nodes | 36 | 55 | |
| Ki67 < 20% | 20 | 35 | 0.411 |
| Ki67 20–60% | 47 | 55 | |
| Ki67 > 60% | 4 | 8 | |
| With disease | 26 | 21 | 0.0497 |
| Disease free | 47 | 79 | |
| NPI ≤ 2.4 | 6 | 9 | 0.997 |
| NPI 2.41–3.4 | 12 | 16 | |
| NPI 3.41–5.4 | 35 | 50 | |
| NPI > 5.4 | 17 | 23 |
ΔNp63/p40+ cancers are defined as having at least one tumour cell that is ΔNp63/p40+ but SMA−. ER; positive for ER but not HER2. ERH; positive for both ER and HER2. H; positive for HER2 but negative for ER. HER2, positive for HER2 (=ERH + H); Values for Ki67 represent the percentage of tumour cells positive for Ki67 antigen; statistical significance was determined by chi‐square test. Data are shown for only one of the Ki67 cut‐offs; using <5% or <40% to define low Ki67 also indicated lack of statistical significance.